OR16-5 Riluzole suppresses growth and enhances response to endocrine therapy in ER+ breast cancer

Approximately 75% of breast cancers are classified as hormone receptor-positive, most of which are estrogen receptor alpha-positive (ER+), which is the primary driver of growth in these tumors. Consequently, endocrine or anti-estrogen therapy is used for treatment. However, despite the benefits of e...

Descripción completa

Detalles Bibliográficos
Autores principales: Bahnassy, Shaymaa, Benitez, Carlos, Cruz, M Idalia, Guerra, Yanira, Ma, Shihong, Persaud, Sonali, Raj, Ganesh, Riggins, Rebecca, Stires, Hillary, Olukoya, Ayodeji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Tumor Biology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629283/
http://dx.doi.org/10.1210/jendso/bvac150.1822

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629283/
http://dx.doi.org/10.1210/jendso/bvac150.1822

Ejemplares similares